3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
3
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Pancreatic Neoplasms
74
Carcinoma, Non-Small-Cell Lung
73
Breast Neoplasms
39
Lung Neoplasms
31
Urinary Bladder Neoplasms
28
Nasopharyngeal Carcinoma
28
Ovarian Neoplasms
25
Neoplasm Metastasis
21
Cholangiocarcinoma
18
Triple Negative Breast Neoplasms
16
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
13
Gallbladder Neoplasms
13
Biliary Tract Neoplasms
13
Uterine Cervical Neoplasms
12
Recurrence
12
Carcinoma, Transitional Cell
12
Nasopharyngeal Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Fallopian Tube Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
9
Lymphoma
7
Carcinoma
7
Bile Duct Neoplasms
7
Lymphoma, Non-Hodgkin
6
Adenocarcinoma
6
Carcinoma, Hepatocellular
5
Adenocarcinoma of Lung
5
Neoplasms by Site
4
Urothelial Cancer
3
Interventions
Cisplatin
6
Pemetrexed
4
Carboplatin
3
Nivolumab
2
Ipilimumab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
ranpirnase
1
raltitrexed
1
durvalumab
1
atezolizumab
1
Vinorelbine
1
Vincristine
1
Talc
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Platinum
1
Mitomycin
1
Injections
1
Gemcitabine
1
Fentanyl
1
Drug Therapy
1
Doxorubicin
1
Cerebral Decortication
1
Analgesia
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Mesothelioma, Malignant
×
Gemcitabine
×
Clear all
NCT03710876
2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3
Completed
53 enrolled
23 charts